Transient proteolytic modification of mesenchymal stromal cells increases lung clearance rate and targeting to injured tissue

Stem Cells Translational Medicine

Volumn 2, Issue 7, 2013, Pages 510-520

  Kerkelä, Erja ^a   Hakkarainen, Tanja ^a   Mäkelä, Tuomas ^b,c   Raki, Mari ^d   Kambur, Oleg ^e   Kilpinen, Lotta ^a   Nikkilä, Janne ^a   Lehtonen, Siri ^b,c   Ritamo, Ilja ^a   Pernu, Roni ^b   Pietilä, Mika ^b   Takalo, Reijo ^c   Juvonen, Tatu ^b,c   Bergström, Kim ^d   Kalso, Eija ^f   Valmu, Leena ^a   Laitinen, Saara ^a   Lehenkari, Petri ^b,c   Nystedt, Johanna ^a  

^a FINNISH RED CROSS BLOOD SERVICE   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Bone marrow stromal cells; Cell adhesion molecules; Cell transplantation; Experimental models; Mesenchymal stem cells

Indexed keywords

CELL SURFACE PROTEIN; PRONASE; TRYPSIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BIOAVAILABILITY; CELL FUNCTION; CELL PROLIFERATION; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LEUKOCYTE ROLLING; LUNG CLEARANCE; MASS SPECTROMETRY; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PROTEIN DEGRADATION; SWINE; T LYMPHOCYTE; TISSUE INJURY; TREATMENT OUTCOME;

RATTUS; SUS;

EID: 84879724854     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0187     Document Type: Article

References (50)

1. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003;5:485-489.
2. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.
3. Uccelli A, Moretta L Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-736.
4. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371: 1579-1586.
5. Salem HK, Thiemermann C. Mesenchymal stromal cells: Current understanding and clinical status. STEM CELLS 2010;28:585-596.
6. Ley K, Laudanna C, Cybulsky MI et al. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7:678-689.
7. Rüster B, Gottig S, Ludwig RJ et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006;108:3938-3944.
8. Steingen C, Brenig F, Baumgartner L et al. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Mol Cell Cardiol 2008;44:1072-1084.
9. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 2009;4:206-216.
10. Devine SM, Cobbs C, Jennings M et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101: 2999-3001.
11. Sackstein R, Merzaban JS, Cain DW et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. NatMed2008;14:181-187.
12. Gao J, Dennis JE, Muzic RF et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12-20.
13. Barbash IM, Chouraqui P, Baron J et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: Feasibility, cell migration, and body distribution. Circulation 2003;108:863-868.
14. Allers C, Sierralta WD, Neubauer S et al. Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice. Transplantation 2004;78:503-508.
15. Kang WJ, Kang H, Kim H et al. Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J Nucl Med 2006;47:1295-1301.
16. Nystedt J, Mäkinen S, Laine J et al. Human cord blood CD34+ cells and behavioral recovery following focal cerebral ischemia in rats. Acta Neurobiol Exp (Wars) 2006;66:293-300.
17. Tolar J, O'Shaughnessy MJ, Panoskaltsis-Mortari A et al. Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. Blood 2006;107:4182-4188.
18. Meyerrose TE, De Ugarte DA, Hofling AA et al. In vivo distribution of human adiposederived mesenchymal stem cells in novel xenotransplantation models. STEM CELLS 2007;25: 220-227.
19. Schrepfer S, Deuse T, Reichenspurner H et al. Stem cell transplantation: The lung barrier. Transplant Proc 2007;39:573-576.
20. Vilalta M, Degano IR, Bago J et al. Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging. Stem Cells Dev 2008;17:993-1003.
21. Fischer UM, Harting MT, Jimenez F et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev 2009;18:683-692.
22. Lee RH, Pulin AA, Seo MJ et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009;5:54-63.
23. Schwarting S, Litwak S, Hao W et al. Hematopoietic stem cells reduce postischemic inflammation and ameliorate ischemic brain injury. Stroke 2008;39:2867-2875.
24. Nystedt J, Anderson H, Tikkanen J et al. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. STEM CELLS 2013 (in press).
25. Laitinen A, Nystedt J, Laitinen S. The isolation and culture of human cord blood-derived mesenchymal stem cells under low oxygen conditions. Methods Mol Biol 2011;698: 63-73.
26. Leskelä HV, Risteli J, Niskanen S et al. Osteoblast recruitment from stem cells does not decrease by age at late adulthood. Biochem Biophys Res Commun 2003;311: 1008-1013.
27. Narahashi Y, Yanagita M. Studies on proteolytic enzymes (pronase) of Streptomyces griseus K-1. I. Nature and properties of the proteolytic enzyme system. J Biochem 1967;62: 633-641.
28. Scheurer SB, Rybak JN, Roesli C et al. Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics 2005;5:2718-2728.
29. Kinter M, Sherman NE. Protein Sequencing and Identification Using Tandem Mass Spectrometry. New York, NY: Wiley-Interscience, 2000.
30. Sarkanen JR, Mannerstrom M, Vuorenpaa H et al. Intra-laboratory pre-validation of a human cell based in vitro angiogenesis assay for testing angiogenesis modulators. Front Pharmacol 2010;1:147.
31. Pietilä M, Lehtonen S, Narhi M et al. Mitochondrial function determines the viability and osteogenic potency of human mesenchymal stem cells. Tissue Eng Part C Methods 2010;16:435-445.
32. Foley JF, Aftonomos B. The use of pronase in tissue culture: A comparison with trypsin. J Cell Physiol 1970;75:159-161.
33. Lee JW, Fang X, Gupta N et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA 2009;106:16357-16362.
34. Anjos-Afonso F, Siapati EK, Bonnet D. In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J Cell Sci 2004;117: 5655-5664.
35. Yagi H, Soto-Gutierrez A, Parekkadan B et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010;19:667-679.
36. Deak E, Ruster B, Keller L et al. Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. Cytotherapy 2010;12:260-264.
37. Murai T, Sougawa N, Kawashima H et al. CD44-chondroitin sulfate interactions mediate leukocyte rolling under physiological flow conditions. Immunol Lett 2004;93:163-170.
38. Zhu H, Mitsuhashi N, Klein A et al. The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix. STEM CELLS 2006;24:928-935.
39. Brooke G, Tong H, Levesque JP et al. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev 2008;17:929-940.
40. Li Y, Chen J, Chen XG et al. Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery. Neurology 2002;59:514-523.
41. Chapel A, Bertho JM, Bensidhoum M et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003;5:1028-1038.
42. Hargreaves K, Dubner R, Brown F et al. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32:77-88.
43. Morris CJ. Carrageenan-induced paw edema in the rat and mouse. Methods Mol Biol 2003;225:115-121.
44. Sarkar D, Spencer JA, Phillips JA et al. Engineered cell homing. Blood 2011;118: e184-e191.
45. Kean TJ, Duesler L, Young RG et al. Development of a peptide-targeted, myocardial ischemia-homing, mesenchymal stem cell. J Drug Target 2012;20:23-32.
46. Cheng H, Byrska-Bishop M, Zhang CT et al. Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell-selectin interaction kinetics. Biomaterials 2012;33:5004-5012.
47. Lee RH, Seo MJ, Pulin AA et al. The CD34-like protein PODXL and α6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 2009;113:816-826.
48. Hung SC, Pochampally RR, Hsu SC et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2007;2:e416.
49. Rosova I, Dao M, Capoccia B et al. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. STEM CELLS 2008; 26:2173-2182.
50. Hemeda H, Jakob M, Ludwig AK et al. Interferon-gamma and tumor necrosis factoralpha differentially affect cytokine expression and migration properties of mesenchymal stem cells. Stem Cells Dev 2010;19:693-706.